相关实验视频

Updated: Jul 9, 2025

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood
07:26

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood

Published on: September 14, 2017

11.2K

在慢性阻塞性肺病中,通过对USP7/p300通路进行下调调节,对内皮原生细胞的系统管理可缓解多器官衰老

Wenhua Wang1, Huaihuai Peng2, Menghao Zeng1

  • 1Department of Intensive Care Unit, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Journal of translational medicine
|December 7, 2023
PubMed
概括

在慢性阻塞性肺病 (COPD) 的小鼠中,静脉注射内皮原生细胞 (EPC) 通过降低USP7/p300通路的调节来抑制多器官衰老,为COPD提供了潜在的新疗法.

关键词:
慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性肺炎.欧洲保险公司 (EPCs) 是一个欧洲保险公司.衰老是一种衰老.系统的管理系统的管理.USP7 USP7 美国在P300上,P300是P300.

更多相关视频

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery08:43

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery

Published on: February 14, 2017

11.0K
Isolation of Primary Mouse Lung Endothelial Cells06:41

Isolation of Primary Mouse Lung Endothelial Cells

Published on: November 10, 2021

5.4K

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188